JPMorgan downgraded Sanofi to Neutral from Overweight with an unchanged price target of EUR 92. The “fruits” of the company’s pipeline seem unlikely to drive a re-rating of the shares until the Phase III readouts start arriving in 2025 for itepekimab and 2026-27 for amlitelimab and frexalimab, the analyst tells investors in a research note. As such, the firm sees limited chance for re-rating for the next 12-18 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNY:
- Regeneron price target raised to $937 from $935 at Jefferies
- Regeneron, Sanofi report Dupixent reduced COPD exacerbations in second trial
- Homology Medicines, Q32 Bio enter all-stock merger agreement
- Sanofi consumer unit attracting interest ahead of spinoff, Bloomberg says
- Madrigal Pharmaceuticals appoints Huntsman as Chief Commercial Officer
